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MASALAH-MASALAH TERAPI DRUG DAN KUALITI KEHIDUPAN BAGI 
PESAKIT DALAM YANG MENGHIDAP PENY AKIT GINJAL 
KRONIK 
ABSTRAK 
Masalah-masalah terapi drug {DTP) merupakan suatu cabaran penting kepada pengamal 
penjagaan kesihatan, ianya juga mempengaruhi morbiditi, mortaliti dan kualiti kehidupan 
pesakit (QoL). Pesakit ginjal kronik (CKD) menerima pelbagai agen farmakoterapi yang 
menyebabkan mereka berisiko tinggi untuk mendapat DTP. Sehingga kini tidak terdapat 
kajian mengenai DTP dikalangan pesakit dalam CKD di Malaysia. Maka kajian ini 
bertujuan untuk menilai DTP dan kualiti kehidupan dengan menggunakan borang kaji 
selidik SF-36 pada pesakit CKD. Satu kajian pemerhatian prospektif telah dijalankan ke 
atas 308 pesakit CKD, berumur 18 tahun dan ke atas yang dimasukkan ke wad perubatan 
Hospital Pulau Pinang . Daripada bilangan ini, 154 pesakit telah didiagnosis mengalami 
penyakit ginjal tahap penghujung (ESRD) (kumpulan ESRD) dan 154 lagi pesakit telah 
di diagnosis mengalami CKD tahap satu ke tahap empat (kumpulan bukan -ESRD). 
Daripada 154 pesakit ESRD yang disusuli, empat orang telah keluar dari hospital atas 
kehendak sendiri dan tiga pesakit telah meninggal dunia di wad perubatan. Manakala 154 
pesakit bukan- ESRD pula, dua pesakit telah keluar wad tanpa pengetahuan manakala 
tiga lagi didiscas keluar wad atas kehendak sendiri. Maka data yang lengkap hanya 
didapati untuk 147 pesakit ESRD dan 149 pesakit bukan-ESRD. DTP telah dikenalpasti 
melalui penilaian carta pengubatan pesakit dan temubual pesakit. DTP telah dibahagikan 
kepada Iapan kategori: Indikasi tanpa drug (IWD), drug tanpa indikasi (DWI), pemilihan 
drug yang tidak sesuai (IDS), pengubahsuaian dos yang tidak sesuai, tindakbalas mudarat 
drug (ADR), interaksi drug (01), ketidaksesuaian pemantauan makmal dan pesakit yang 
tidak patuh. Manakala QoL pesakit telah dinilai dengan menjawab sendiri soalselidik 
tervalidasi SF-36. SPSS versi 12 telah di gunakan untuk analisis data. Ujian "Chi-
square", ujian tepat "Fisher's", hubungan angkatap dan analisis regresi Jelurus telah di 
gunakan apabila sesuai dan nilai P <0.05 dianggap sebagai signifikan statistik. Purata 
umur pesakit ESRD ialah 53±15.3 tahun dan 48.9±17.9 tahun untuk pesakit bukan-
XVlll 
ESRD. Pesakit ESRD mengalami lebih DTP berbanding pesakit bukan-ESRD (P<O.OOI). 
· DTP yang sering terjadi dikalangan pesakit ESRD adalah IWD (20.9%), IDS (20.7%) 
dan DI (19.4%) sementara dikalangan pesakit bukan-ESRD pula adalah IWD (20.3%), DI 
(19.0%) dan IDS (18.0%). Peningkatan umur, jantina perempuan, tempoh hospitalisasi 
yang panjang dan tempoh CKD telah didapati ada hubungkait dengan peningkatan DTP. 
Selanjutanya, hipertensi, penyakit jantung koronari (CHD), peningkatan bilangan drug, 
drug antihipertensif dan drug anemia juga mempunyai hubungkait dengan peningkatan 
DTP. Penilaian kualiti kehidupan telah menunjukkan pesakit ESRD mempunyai QoL 
rendah yang signifikan secara statistik berbanding bukan ESRD (P<O.OO 1 ). Manakala, 
faktor-faktor seperti peningkatan umur, bangsa India atau bangsa lain, bilangan 
komorbiditi yang tinggi, klearans kreatinin yang rendah, ADRs, drug-drug anti-infektif, 
dialisis dan tempoh CKD telah didapati menpunyai hubungkait dengan penurunan QoL 
(P<0.05). 
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'· 
DRUG THERAPY PROBLEMS AND QUALITY OF LIFE IN PATIENTS WITH 
CHRONIC KIDNEY DISEASE 
ABSTRACT 
Drug therapy problems (DTP) are a significant challenge to health care providers that are 
associated with morbidity, mortality and patient's quality of life (QoL). Patients with 
chronic kidney disease (CKD) receive a wide range of pharmacotherapeutic agents and 
are therefore at higher risk to experience DTP. To date, DTP in hospitalized CKD 
~\ patients have not been investigated in Malaysia. Thus, this study was aimed to assess 
;;:, 
£· 
DTP and to evaluate QoL using SF-36 instrument in CKD patients. A prospective 
observational study was conducted among 308 patients with CKD who were aged 18 
years or older and admitted to the general medical ward of Penang General Hospital 
(PGH). Of this, 154 patients had confirmed diagnosis of end stage renal disease (ESRD) 
(ESRD group) and 154 patients had the diagnosis of stage one to stage four of CKD (non-
ESRD group). Out of the 154 ESRD patients initially followed in the study, four patients 
took discharge at their own risk and three patients died in the medical ward during the 
follow-up. On the other hand, of the 154 non-ESRD patients, two patients absconded 
from the medical ward and three patients took discharge at self risk. Hence, data with 
complete information were available for 14 7 ESRD patients and 149 non-ESRD patients. 
DTP were identified through review of patients' medical charts and patients interviews. 
DTP were categorized into eight: indication without drug (IWD), drug without indication 
(OWl), improper drug selection (IDS), inappropriate dosage adjustment, adverse drug 
reactions (ADR), drug interactions (01), inappropriate laboratory monitoring and 
patient's non-adherence. While, patients' QoL was assessed using a validated and self 
XX 
administered SF-36 QoL questionnaire. Statistical Package for Social Science (SPSS) 
version 12 was used for data analysis. Chi-square test, Fisher's exact test, correlation 
coefficient and linear regression analysis were used wherever appropriate and P-value 
<0.05 was considered as statistically significant. The mean age of patients was 53 ± 15.3 
years and 48.9 ± 17.9 years for the ESRD and the non-ESRD groups, respectively. ESRD 
pati~nts had more DTP than non-ESRD patients {P<0.001). The most common DTP 
among the ESRD patients were: IWD (20.9%), IDS (20.7%) and Dl (19.4%) whereas, 
among the non-ESRD group, the most common DTP were: IWD (20.3%), DI (19.0%), 
and IDS (18.0%). Increased age, female gender, duration of hospitalization and duration 
of CKD were found to be significantly associated with the number of DTP. In addition, 
hypertension, coronary heart disease (CHD), number of drugs, antihypertensive drugs 
and anaemia drugs were also found to be associated with number of DTP. QoL 
evaluation revealed that ESRD patients had significantly lower QoL than their non-ESRD 
counterparts (P<0.001). Factors such as increased age, Indian or other race, number of 
comorbidities, creatinine cleatal}ce, ADRs, anti-infective drugs, dialysis, duration of 
CKD were found to be associated with a lower QoL (P<0.05). 
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CHAPTER ONE 
INTRODUCTION 
• 1.1 Background 
The intention of prescribing drugs to patients is treatment, prophylaxis or 
,o' 
~, diagnosis of medical conditions; however, these drugs may have negative effects on 
~·· r patients if not used appropriately. Pharmacists can play an important role in identifying 
~, drug therapy problems (DTPs), resolving actual DTPs and preventing potential DTPs 
f, 
~, through careful pharmaceutical practices. 
A DTP is defined as an undesirable event or risk experienced by a patient, 
which involves or is suspected to involve drug therapy (Strand et al., 1990). The 
occurrence of a DTP could prevent or delay patients from achieving desired therapeutic 
goals. An actual DTP is an event that has already occurred in a patient, whereas a 
potential DTP is an event that is likely to develop if pharmacists do not make any 
appropriate interventions (Rovert et al., 2004). DTPs are significant challenge to health 
care providers and may affect morbidity, mortality and a patient's quality oflife (QoL). 
Several studies have shown that patients with end stage renal disease (ESRD) are 
among those at high risk for DTPs (Grabe et a/., 1997; Manley et al., 2003b; Grabe et 
al., 1997). 
As of 2005, the prevalence rate of ESRD in Malaysia was estimated to be 100 
per million populations (USRDS, 2005c). The increasing number of ESRD patients in 
Malaysia certainly raises the risk of DTPs in these patients. Therefore, identifying and 
1 
resolving DTPs and improving the QoL of ESRD patients should be of the utmost 
importance to health care providers. 
1.2 Literature Review 
A literature review was performed to evaluate clinical pharmacy, 
pharmaceutical care, DTP, chronic kidney disease (CKD) and co-morbidities associated 
withESRD. 
1.2.1 Clinical Pharmacy 
Clinical pharmacy practices include all services typically provided by 
pharmacists practicing in hospitals, community pharmacies, nursing homes, home-
based care services and clinics. The American College of Clinical Pharmacy (ACCP) 
has defined clinical pharmacy as a health science specialty where the pharmacist 
applies the scientific principles of pharmacology, toxicology, pharmacokinetics and 
therapeutics to the care of patients (Cipolle et a/., 1998). In Europe, the European 
Society of Clinical Pharmacy has defined clinical pharmacy as "a health specialty, 
which describes the activities and services of the clinical pharmacist to develop and 
promote the rational and appropriate use of medicinal products and devices" (The 
European Society of Clinical Pharmacy, 2007). 
Clinical pharmacy focuses on population needs with regard to medication 
administration, use and effects on the patient (The European Society of Clinical 
Pharmacy, 2007). In order for clinical pharmacists to make interventions, they must 
have a strong clinical background and evaluative tools to correctly judge the evidence 
available for various treatments (Manuel et a/., 2007). Thus, they mus1 
2 
·· understanding of disease characteristics and their progression, m addition to the 
characteristics of various medications and their mechanisms of action, their 
formulations and the ways in which they interact with the human body. Furthermore, 
clinical pharmacists need to be able to evaluate the real value of a drug and analyse 
randomized controlled trials and epidemiological studies. 
1.2.1(a) The Role of a Clinical Pharmacist 
The role of a clinical pharmacist is to maximise the clinical effects of medicines 
by ensuring the selection of the most effective drugs for each patient, minimising 
adverse drug events by monitoring the drug therapy course of the patient and improving 
the patient's adherence with the drugs (The European Society of Clinical Pharmacy, 
2007). Clinical pharmacists also contribute to minimising the costs of drug therapy and 
health care by providing cost effective alternatives (Cipolle eta/., 1998). 
Clinical pharmacists ensure the correct use of drugs at three levels: 1) before the 
drug is prescribed, 2) during the time of drug prescription, and 3) after the drug is 
prescribed (Scroccaro et a/., 2000). The role of the clinical pharmacist prior to the 
prescription of a drug can be explained in the context of conducting clinical trials and 
providing drug information. During the prescription stage, the clinical pharmacist 
detects and prevents drug interactions (DI), adverse drug reactions (ADR) and 
medication errors. The clinical pharmacist also pays special attention to the dosage of 
drugs that require serum drug concentration monitoring. After the drug is prescribed, 
the clinical pharmacist must communicate with the patient. By conducting patient 
counselling, the clinical pharmacist can improve a patient's adherence with the drugs, 
monitor treatment response and improve the patient's awareness of their drugs. The 
3 
f ~.' 
~clinical pharmacist also conducts outcomes research to evaluate the effectiveness of 
; alternative drug therapy (Scroccaro eta/., 2000). 
t.2.1(b) The Impact of Clinical Pharmacy Services 
The intervention of clinical pharmacists for a period of one month in an 
J; 
~ intensive care unit (ICU) at Penang General Hospital (PGH) in Malaysia resulted in a ~· 
I' ,. 
total net cost savings of Ringgit Malaysia (RM) 15253.34 (United States Dollars (USD) 
$4,014); hence, clinical phannacy services were suggested as a routine practice in the 
hospital (Zaidi et a/., 2003). In a review of nindomised controlled studies assessing 
DTP and health outcomes in the elderly, clinical pharmacy services also proved to be 
beneficial in reducing the occurrence of DTPs (Hanlon eta/., 2004). Chisholm (2001) 
and colleagues reported that renal transplant patients who received clinical pharmacy 
services had a significantly higher adherence rate (P< 0. 00 1), longer duration of 
adherence (P<0.05) and greater achievement of target serum concentration of 
immunosuppressive drugs (cyclosporine and Tacrolimus) (P<0.05) compared to those 
who "did not receive any clinical pharmacy services. 
1.2.2 Pharmaceutical Care Practice 
Pharmacists with their pharmaceutical knowledge and skills are in the best 
position to work together with physicians and other health care providers to manage 
patient drug therapy and improve QoL. A concept of pharmaceutical care based on this 
idea was first formulated in the United States of America (USA). 
Hepler and Strand (1990) defined pharmaceutical care as the responsible 
provision of drug therapy for the purpose of achieving definite outcomes that improve 
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the patient's QoL. Pharmaceutical care can also be defined as a practice in which the 
phannacist takes responsibility for a patient's drug-related needs and is held 
accountable for this commitment (Strand, 1997). 
The four dimensions of the philosophy of pharmaceutical care in practice are 
social needs, a patient-centred approach to meet these needs, the development of caring 
through a therapeutic relationship and a description of the practitioner's specific 
responsibilities (Cipolle et a/., 1998). Practitioners of pharmaceutical care can meet 
social needs by minimising drug-related morbidity and mortality. In order for the 
practitioner to meet these social needs, he or she must take a patient-centred approach. 
By using a patient-centred approach, then, the practitioner becomes responsible for the 
patient's drug-related needs such as patient concerns, expectations and understanding 
of illness. 
Caring through a therapeutic relationship is collaboration between the patient 
and the pharmaceutical care practitioner in order to meet the patient's health-related 
needs. The practitioner in his role agrees to assess the patient's needs and follow the 
patient's care to ensure that effective interventions are being made. On the other hand 
the patient agrees to provide accurate and complete information to the practitioner so 
that the practitioner can make knowledgeable decisions. 
The specific responsibilities of a pharmaceutical care practitioner include 
ensuring that the most effective and safest drugs are prescribed to patients and that a 
patient's drug therapies are convenient enough to be followed as indicated. It is the 
pharmacist's responsibility to ensure that the patient is able to adhere to medication 
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m order to produce positive outcomes. In addition, the pharmacist ts 
responsible for identifying, resolving and preventing DTPs. 
t.2.2(a) The Impact of Pharmaceutical Care 
The goal of instituting pharmaceutical care services is to reduce increasing 
. levels of drug related morbidity and mortality associated with drug use and to prevent 
· the high financial cost of adverse drug events (Cipolle eta/., 1998). It has been reported 
that pharmaceutical care in ambulatory haemodialysis (HD) units has improved 
medication adherence, provided drug information, raised awareness of inappropriate 
medication and improved biochemical and therapeutic responses to medications 
(Manley et a/., 2003a; Grabe et a/., 1997). In addition, pharmaceutical care services 
have also proven to be successful in effectively managing diseases such as 
hypertension and diabetes mellitus (DM), while improving QoL for patients (De Souza 
eta/., 2007; Jaber et al., 1996). 
1.2.2(b) Drug-Related Morbidity a._d Mortality 
Drug-related morbidity is a failure of a drug therapy to produce the intended 
therapeutic outcomes, either due to treatment failure or the development of new 
medical indications (Hepler and Strand, 1990). It has been reported that adverse drug 
events are the main cause of death as well as hospital admission in ambulatory patients. 
The total cost of drug related morbidity and mortality in the ambulatory setting in the 
USA in 2000 was estimated to be USD $177 billion, which was more than double the 
cost estimated in 1995 (USD $76 billion) (Ernst and Grizzle, 2001). Still, other 
investigators have reported that 27.6% of adverse drug events are preventable (Gurwitz 
eta/., 2003). 
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1.2.2( c) Identification of DTP 
Identifying DTPs is one of the objectives of the pharmaceutical care process. 
Clinical pharmacists can play an important role in identifying and resolving DTPs 
through cooperation with patients and other health care providers (Grabe et a/., 1997). 
Potential and actual DTPs can be identified thorough medication profile reviews, and 
these problems can be prevented by monitoring therapeutic plans (Britton and Lurvey, 
1991). A number of actual DTPs can be resolved with patient counselling and 
recommendations to prescribers. 
1.2.3 Categories of DTPs 
Cipolle et a/. ( 1998) broadly categorized DTPs into eight groups. These 
investigators ensured that all DTPs occurring in clinical practice would fall into these 
eight categories. Each pharmacist must be familiar with these categories and their 
causes in order to provide the best pharmaceutical care possible for the patient. The 
categories of DTPs are as follows. 
1.2.3(a) Indication without Drug (IWD) 
An indication without drug (IWD) occurs when there is a need to treat a 
;: previously untreated indication, to add synergistic or potentiating drug therapy or to 
~' 
~· ~. deliver prophylactic or preventive drug therapy. For example, if a patient is being 
f· [-'· 
,, 
~~ 
~- appropriately treated for peripheral vascular disease but does not receive treatment for ~ ~ developing anaemia, the primary condition is being treated but no drug therapy is being 
given to treat the new illness (Strand et al., 1990). Another example of IWD is using a 
single drug therapy instead of an appropriate combination of drugs to treat a medical 
condition (Cipolle et al., 1998). 
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In a prospective study conducted by Manley eta/. (2003b ), IWD was the second 
common DTP among HD patients with DM, accounting for 17.5% of all DTPs 
1u,...u ..... ..., .... during the study. In this study, the causes of IWD were patients with high 
risk who had no acetylsalicylic acid (ASA) prescription, patients with 
failure who had no angiotensin converting enzyme (ACE) inhibitor 
. prescription and post myocardial infraction (MI) or stroke patients who had no ASA 
therapy. It was also reported that more than half of DTPs identified in ESRD patients at 
the time of hospital admission were due to an IWD (Ong et a/., 2006). The report 
revealed that most of the symptoms were not treated due to a lack of communication 
·· between patients and healthcare providers. 
Several studies have reported that the need for additional drug therapy is one of 
the most common DTPs in patients admitted to internal medicine wards (Blix et a/., 
2006; Blix et a/., 2004; Viktil et a/., 2004). In addition, a report from a sample of 
elderly patients who received pharmaceutical care for one year at the University of 
"Minnesota revealed that IWD was the most common DTP identified, accounting for 
32% of all DTPs (Rao et a/., 2007). Hypertension, DM, arthritis, chronic heart disease 
(CHD) and osteoporosis were the most common medical conditions requiring 
additional drug therapy. 
1.2.3(b) Drug without Indication (DWI) 
A drug without indication (DWI) occurs when a patient takes an unnecessary 
drug therapy for which the clinical indication is not present at that time (Cipolle et a/., 
1998). There are several causes for DWI. First, the medical condition could be more 
appropriately treated with non-drug therapy such as diet, exercise or surgery. Second, 
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e patient might be on a drug therapy to treat an avoidable ADR of another drug. 
· d, narcotics abuse, tobacco and alcohol consumption might all be causing the 
\oblem. Finally, multiple drug therapies might be used to treat a condition that 
requires only a single drug therapy. For example, some patients receive more than one 
raxative for the treatment of constipation; some patients receive more than one anti-
fdiarrhoeal for the treatment of diarrhoea; and some patients receive more than one 
~ 
f;f 
ianalgesic for pain treatment. 
~; ... 
~· 
1 
DWis were reported to be a major DTP among HD patients, accounting for 
29.8% of all DTPs (Manley eta/., 2003b). In addition, a prospective study conducted to 
compare DTPs in patients admitted to cardiology, geriatric, respiratory and 
rheumatology departments found that DWI was more common in geriatric patients 
compared to the other three groups (P<O.OJ) (Viktil eta/., 2004). In a study conducted 
in the ICU of PGH, Malaysia, unnecessary drug therapy was the most common DTP 
identified, and among these DWis, 39% were accepted by the physicians (Zaidi et al., 
2003). 
1.2.3(c) Improper Drug Selection (IDS) 
An IDS is a situation in which the patient has been prescribed the wrong drug. 
Examples of this type of DTP include the following (Strand et al., 1990 and Cipolle et 
al., 1998). 
1. The drug therapy used to treat the patient's medical condition is ineffective. 
11. A much more effective drug exists but was not prescribed to the patient. 
111. A contraindicated or an allergic drug was prescribed to the patient. 
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iv. The patient received combination drug therapy instead of an equally effective 
single drug therapy. 
v. The patient received an expensive drug instead of a cheaper and equally effective 
drug. 
J 
Kaplan et al. (1994b) reported that 40% of HD patients had potentially 
~- suboptimal or ·ineffective drug therapy and needed an alternative drug selection. 
~ 
~. Soendergaard et al. (2006) reported that 18.4% of DTPs in general practice were due to 
~ inappropriate selection of drugs. It has also ·been reported that IDS is very common 
!i 
~ ,. 
~ (36.8%) in type 2 DM patients (e.g. prescribing insulin instead of oral anti-diabetic 
:~ 
;;· 
agents and contraindications due to prescribing metformin for patients over the age of 
70 years) (Haugb01le et al 2006). 
1.2.3(d) Inappropriate Dosage Adjustments 
Inappropriate dosage adjustment can be classified into two sub-categories under 
dose (UD) and over dose (OD). 
i. Under Dose (UD) 
It is often challenging for health care providers to ensure appropriate medication 
dosing for patients who are on dialysis due to the potential increase in co-morbidities 
over time and changing laboratory parameters, pharmacokinetic and pharmacodynamic 
parameters and dialysis treatments. Careful and continual monitoring of patient 
progress in addition to drug dosage adjustments by a clinical pharmacist that take into 
account all appropriate drug, disease, and patient specific information may decrease the 
number of dosing problems in ESRD patients (Pillans et al., 2003). In addition, 
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parameters such as age and body weight can often be useful to assist in determining the 
optimal drug dose for a patient (Cipolle eta/., 1998). 
The causes ofUD are inappropriate dosing frequency, short duration of therapy, 
inappropriate drug storage (e.g., storing drugs in an excessively hot or humid place, 
leading to degradation of the dosage form and sub-therapeutic dosing), inappropriate 
drug administration and DI (Rover eta/., 2004). 
An example of UD in dialysis patients is decreased erythropoietin (EPO) dosing 
with regard to recent haemoglobin values (John and Marc, 2004). Other reasons such as 
dosage calculation errors and incorrect conversion of different formulations of drug 
therapy could also lead to suboptimal treatment (Cipolle eta/., 1998). 
Ong eta/. (2006) reported that drug UD was the second most common DTP in 
ESRD patients (13.6%) that took place at the time of hospital admission. The 
investigators reported that more than half of drug UD problems were due to inadequate 
communication between patients and healthcare providers regarding the medication. 
Manley et a/. (2003a) reported that contradictions between information provided by 
HD patients during a drug interview and information from electronic medical records 
were found to be predominantly associated with dosing errors (34.5%). Half of these 
dosing errors resulted in drug UD. It has also been reported that drug UD is one ofthe 
most common DTPs in elderly patients (Rao eta/., 2007). 
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• Over Dose (OD) 
As stated by Cipolle et a/. (1998), when a patient receives a dose of an agent 
is too high and experiences a dose-dependent or concentration-dependent toxic 
.... J...1. ........ he or she is experiencing a DTP. In patients with decreased renal function, the 
-v·• .. ·J of the kidney to eliminate drugs and their metabolites is decreased, which in turn 
to the accumulation of drugs and toxic products in the kidney. For instance, if the 
of procainamide is not adjusted for patients with compromised renal function, N-
~""'"'.,'11.,. .. r, ... ainamide can accumulate in the kidney (Cipolle et al., 1998). 
Pillans et a/. (2003) reported that the doses of 44.8% of drugs with a narrow 
therapeutic index were inappropriately high in patients with creatinine clearance (Clcr) 
~ 40 ml/min at the time of hospital admission. Drug OD in ESRD patients could also 
result from contradictions between information provided by patients and information 
obtained from electronic medical records (Ong eta/., 2006). 
1.2.3(e) Adverse Drug Reactions (ADRs) 
As stated by Cipolle et a/. (1998), "ADRs can be defined as undesirable 
negative effects caused by the medication that were not predictable based on its dosage 
concentration or pharmacological action." According to the WHO, ADR is described as 
"A response to a drug which is noxious and unintended, and which occurs at doses 
normally used for the prophylaxis, diagnosis or therapy of disease, or for the 
modification of physiological function" (WHO, 1972). A patient may experience an 
ADR due to the administration of an unsafe drug, an allergic reaction, incorrect drug 
administration, Dl, rapid dosage increment or decrement or undesirable effects of the 
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i-
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t 
g that could not be predicted. For example, bleeding due to a higher dose of 
. ticoagulant drugs such as warfarin or heparin is an ADR (Lacy eta/., 2004-2005). 
A prospective study conducted to compare the incidence of hospital admissions 
~ue to ADRs in the general medical ward of two hospitals revealed that 4.1% out of 
z,499 medical admissions and 5. 7% out of 2,933 medical admissions were due to 
ADRs (Levy et al.; 2004). In addition, Suh eta/. (2000) reported that both length and 
\cost of hospital stay were significantly higher (P<O.OJ) for patients who experienced 
~ADRs than for those who did not. 
Manley eta/ (2003c) reported that ADRs were the second most common DTP 
r identified in HD patients. ADRs are also very common in elderly patients (Hajjar eta/., 
f. 
I 
, 2003; Williamson and Chopin 1980). Patients who are on polypharmacy, those with 
· multiple chronic medical conditions, those with a history of ADRs and those with 
dementia are at a greater risk for ADRs (Hajjar et al., 2003). Furthermore, non-steroidal 
anti-inflammatory drugs (NSAIDs), antibiotics and antihypertensive agents were 
among drugs commonly associated with ADRs, accounting for 26.5%, 23.6%, and 
17.7% of hospital admission cases, respectively (Capuano et al., 2004). 
1.2.3 (t) Drug Interactions (Dis) 
Dis result from a drug-drug, drug-food and drug-laboratory interactions 
(Cipolle et al., 1998). They can occur in patients receiving drugs from different 
pharmacological classes as well as within the same pharmacological class. Calculates 
can displace first generation hypoglycaemic agents from protein binding sites and may 
potentate hypoglycaemia in DM patients. 
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A DI between calcium salts and iron products is one of the most common seen 
;in ESRD patients (Grabe et a/., 1997). Milk can inhibit the absorption of oral iron 
'preparations (Lacy et al., 2004-2005). Drugs such as ascorbic acids, beta-lactam 
antibiotics (e.g., cephalosporins and penicillins), levodopa and salicylates have all been 
well-documented to interfere with urine glucose testing (Rotbblatt and Koda-Kimble, 
1987). 
Gr~be eta/. (1997) reported that Dis were common (27.5%) in outpatient HD 
patients. Another study performed to compare the frequency of DTPs among patients 
admitted to cardiology, geriatrics, respiratory and rheumatology wards revealed that DI 
was most common (12.2%) in patients admitted to the cardiology ward compared to the 
other three wards (Viktil eta/., 2004). 
1.2.3(g) Inappropriate Laboratory Monitoring 
Laboratory tests should be used to monitor a patient's drug therapy and ensure 
that co-morbid conditions are adequately identified and treated (Manley et al., 2003b). 
If the laboratory monitoring needs of a patient's therapy are not being considered, then 
the patient might be experiencing a DTP. 
Examples of inappropriate laboratory monitoring are seen in patients with high 
cardiovascular risk without monitoring of their fasting lipid profile, blood pressure 
(BP) or blood sugar. Other examples of inappropriate laboratory monitoring include 
patients who have been prescribed long-term aluminium-binding drugs without 
measuring aluminium levels (normal serum aluminium concentration = 1-30 ng/ml) 
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,and patients who have been prescribed amiodarone therapy or have a history of thyroid 
disease without getting a thyroxine level monitoring (Manley eta/., 2003b). 
Inappropriate laboratory monitoring is very common among ambulatory HD 
patients (Manley eta/., 2005; Manley eta/., 2003b). The need for laboratory tests was 
found to be one of the most frequent DTPs in inpatients and was also found to be 
associated with a number of clinical and pharmacological risk factors (P<O.OJ) such as 
reduced renal function (Clcr ::::; 50 ml/minute), reduced liver function and increased 
number of drugs (~ 5 drugs on admission) (Blix et a/., 2004). In addition, patients 
admitted to the cardiology department were reported to be more likely to experience 
inappropriate laboratory monitoring (25.2%) compared to patients admitted to geriatric, 
respiratory and rheumatology departments (Viktil eta/., 2004). 
1.2.3(h) Patient Non-adherence 
The term "adherence" is preferred over "compliance" in medical practice 
(Tilson, 2004). Compliance suggests that the patient acquiesce or obey the physician's 
instructions, while adherence defines the patient as an intelligent and independent 
people who is able to make medical treatment decisions based on the recommendations 
of the prescriber. The main difference between adherence and compliance is that 
adherence requires the patient's agreement to the prescriber's recommendations. 
A patient's non-adherence to a drug regimen can be defined as the patient's 
inability or unwillingness to follow a drug regimen that has been prescribed by the 
practitioner and judged to be clinically appropriate, effective and able to produce the 
desired outcome without harmful effects (Cipolle eta/., 2004). Non-adherence can be 
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to a number of reasons: some are within the patient's control and some are beyond 
(Strand et a/., 1990). A patient's non-adherence to a drug regimen can occur for 
l'l'e:ascms that fall into both of these categories depending on the nature of the cause. 
111 ............. problems can prevent patients from buying the appropriate drug, and failures 
the drug distribution or administration system can also contribute to a patient's non-
adherence (Cipolle et a/., 1988). Factors such as vision, hearing, health literacy, 
and- social and financial resources may further complicate matters in older 
·patients' adherence to pharmacological prescriptions (Murray eta/., 2003). 
Measuring a patient's adherence to a drug regimen is often difficult. One of the 
most useful methods to measure patient adherence is a patient interview (Fletcher et al., 
1979). Pill counting is another method but suffers from the major drawback that 
patients rarely bring all of their medications to the ward. Another established method is 
therapeutic drug monitoring using blood and urine tests (Joyce and Bert, 1991). The 
four major strategies to enhance patient adherence to a drug regimen include patient 
education, planning a dosing schedule that fits into the patient's life-style, clinic 
scheduling for patient follow-up and communication between the patient and physician 
(Joyce and Bert et al, 1991). 
A study of HD patient adherence to a drug regimen showed that 50.2% of them 
were non-adherent to a drug regimen, and 49.5% were non-adherent to fluid restrictions 
(Bame et al., 1993). Other investigators reported that 67% of HD patients missed an 
average of 3.4 medication doses (Kaplan et a/., 1994b ). In a sample of elderly patients 
who received pharmaceutical care in their homes for one year, non-adherence to drug 
therapy was the most common DTP identified, comprising 32% of all DTPs (Rao et al., 
16 
. The reasons for patients' non-adherence to drug therapy were poor 
.•t.2.4 Chronic Kidney Disease (CKD) 
CKD is increasingly becoming a chronic medical condition of public health 
· concern. In 2002, the National Kidney Foundation-Kidney Disease Outcome Quality 
Initiative (NKF-KIDOQI) developed a clinical practice guideline in the USA. The 
guideline introduced the terminology of chronic kidney disease (CKD) and a 
classification scheme to promote early disease detection, delay disease progression and 
prevent related complications. 
1.2.4(a) Definition 
l; CKD is defined as a glomerular filtration rate (GFR) ~ 60 mllminute/1.73m
2 
or 
~ a GFR 2: 60 ml/minute/1.73m2 in the presence of kidney damage for more than three r 
~ 
months (National Kidney Foundation, 2002). 
1.2.4(b) Assessment of Kidney Function 
Estimation of GFR is very important in the clinical management of patients 
with CKD. GFR is used to assess the presence and degree of renal function and helps in 
performing dosage adjustments ofrenally excreted drugs. The NKF-KDOQI guidelines 
recommend the modification of diet in renal disease (MDRD) and the Cockcroft-Gault 
equation as a useful measurement to estimate GFR (National Kidney Foundation, 
2002). Therefore, serum creatinine (SCr) cannot be used alone to assess the level of 
kidney function due to the nonlinear correlation between SCr and kidney function 
(Shemesh eta/., 1985). 
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(i) Cockcroft-Gault Equation 
The Cockcroft-Gault equation was derived from 249 inpatients (96% male, age 
range 18-92 years) with mild renal dysfunction at the Queens Mary Veterans Hospital 
in Canada based on a single measurement of 24-hour Clcr (Cockcroft and Gault 1976). 
The Cockcroft-Gault equation provides a quantitative estimation of Clcr from SCr. 
Cockcroft-Gault equation: 
.. · Men: Clcr (ml/min) = [(140-age) x weight (kg)] 
SCr (mg/dl) x 72 
Women: Clcr (ml/min) = [(140-age) x weight (kg)] x 0.85 
(SCr (mg/dl) x 72) 
Body surface area (BSA)-adjusted Cockcroft-Gault equation 
Men: Clcr (ml/min) = [(140-age) x weight (kg)] x 1.73 m2/ BSA_ 
(SCr (mg/dl) x 72) 
Women: Clcr (ml/min) = [(140-age) x weight (kg)] x 1.73 m2/ BSA_x 0.85 
(SCr (mg/dl) x 72) 
(a) Limitations of Cockcroft-Gault Equation 
The Cockcroft-Gault equation depends on SCr, which is associated with the 
tubular secretion of creatinine. This could lead to overestimation of GFR by 10 to 40% 
in individuals with normal renal function (National Kidney Foundation, 2002). In 
addition, SCr can be influenced by many non-renal factors such as diet (e.g., vegetarian 
diet and creatinine supplements), body mass (e.g., amputation, malnutrition and 
emaciation) and drug therapy (e.g., cimetidine and trimethoprim) (Larsson eta!., 1980; 
Myre et al., 1987). Despite these limitations, the Cockroft-Gault equation has been 
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widely used to determine drug dose individualization based on kidney function in the 
:clinical setting (Patel, 2004; Pillans et al., 2003; Chertow et al., 2001). 
i. ('') ~ II 
1
·.· 
MDRD Equation 
The MDRD equation was introduced in 1999 to overcome the limitations of 
. 
i Clcr-based estimation of GFR. In 1999, the 6-variable MDRD equation was derived 
~ 
i: 
' from an MDRD· population of 1,628 patients with non-diabetic CKD (mean GFR 40 
: mVminute/1.73m2) who concomitantly had GFR measurements using an iothalamate 
(Levey et al., 1999). This equation was developed using patient variables including 
age, SCr, blood urea nitrogen (BUN), albumin, race and gender. Later in 2000, an 
abbreviated 4-variable version of the MDRD equation based on only age, gender, race 
· and SCr level was introduced and has become the most accepted and used equation in 
outpatient clinical settings, superseding the 6-variable MDRD equation and the 
Cockcroft-Gault equation. 
Estimated GFR (6-variable MDRD equation) 
eGFR = 170 x (SCr) - 0·999 x (Age) - 0·176 x (0. 762 if female) x ( 1.180 if African 
American) x (BUN) - 0·170x (Alb) +0·318 
Estimated GFR ( 4-variable MDRD equation) 
eGFR = 186 x (SCr) · 1.1s4 x (Age)- 0·203 x (0.742 if female) x (1.210 if African 
American) 
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,(b) Limitations of MDRD 
Estimation of GFR using MDRD resulted in underestimation of true GFR in 
,healthy individuals, kidney donors and patients with type 1 DM (Lin et a/., 2003; 
/ 
)brahim eta/., 2005). In addition, the 1251-iothalamate (iGFR) was reported to be more 
reliable in measuring the actual level of GFR compared to MDRD equations in 
~hospitalized patients with advanced renal disease (Poggio et a/., 2005). The MDRD 
!: 
1 equations have not been validated in children, pregnant women, the elderly (older than 
,, 
I 
~, 70 y~ars) or ethnic subgroups other than Caucasians and African Americans. 
f 
! 
i' ~ 
f ~· 1.2.4(c) Classification of CK.D 
' !
The NKF-KDOQI has classified CKD into five stages, irrespective of the 
~' underlying cause and based on GFR. 
· Stage 1: Kidney damage with normal or increased GFR (GFR ~ 90 ml/minute/ 
Stage 2: Kidney damage with a mild decrease in GFR (GFR 60-89 ml/minute/1.73m2) 
Stage 3: Moderate decrease in GFR (GFR 30-59 ml/minute/1.73m2) 
Stage 4: Severe decrease in GFR (GFR 15-29 ml/minute/1.73m2) 
Stage 5: Kidney failure (GFR < 15ml/minute/1.73m2) (ESRD). 
1.2.4( d) Risk Factors for CK.D 
Risk factors for CKD include DM, high BP, proteinurea, family history of renal 
disease, increasing age, hyperlipidaemia and tobacco usage (DiPiro et al., 2002). As 
recommended by the NKF-KDOQI (2002), individuals at risk for CKD should undergo 
testing for markers of kidney damage such as proteinurea, urine sediment, dipstick for 
red blood cells (RBC) and white blood cells and imaging tests of the kidneys. 
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Treatment of CKD includes specific therapy based on the diagnosis, evaluation 
management of co-morbidities. The goals of these strategies also include slowing 
. 
loss of kidney function, prevention and treatment of cardiovascular disease and 
complications of decreased kidney function. If signs and symptoms of uraemia are 
nresertL, there should also be preparation for kidney failure, dialysis or transplantation. 
1.2.5 End Stage· Renal Disease (ESRD) 
. 1.2.5.1 Epidemiology of ESRD 
The number of ESRD patients worldwide reported by the United States Renal 
Data System (USRDS) in 2005 has risen from 888,000 in 1999 to 1,129,000 in 2003 
(USRDS, 2005c). The prevalence of ESRD in the USA, Taiwan and Japan was 1,509, 
1,631, and 1,797 per million people, respectively. As of 2005, the lowest prevalence 
was found in the Philippines, Bangladesh and Russia. As reported by the USRDS in 
2005, Malaysia was ranked the fifth highest nation in terms of ESRD incidence rate for 
patients between 45 and 64 years old, after Taiwan, Japan, the USA and Spain 
(USRDS, 2005c). It was reported that DM was the most common cause of ESRD in 
Malaysia; however, the number of dialysis patients with DM showed a decline in 2005 
a" compared to the number in the past 10 years (Lim et a/., 2005). The second most 
~i' 
t r~ 
~ 
F· 
~· 
common cause of ESRD was hypertension, while the underlying cause remained 
unknown in 20% of cases. Glomerulonephritis and systemic lupus erythematosus 
~· accounted for 4% and 1% ofESRD cases, respectively. 
~~ ~-
rr· 
t ~,·_ 
;. 1.2.5.2 Co-morbidities of ESRD !· 
r 
Co-morbidities of ESRD include cardiovascular diseases, hypertension and 
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'.2.5.2 (a) Cardiovascular Diseases 
(i) Definition 
Cardiovascular diseases are those that affect the cardiovascular system such as 
heart failure, arrhythmia, CHD, Ml, hyperlipidaemia, hypertension, stroke and venous 
<, 
thromboembolism. Heart failure, also known as congestive cardiac failure, is a 
tcondition in which the heart is unable to pump a sufficient amount of blood through the 
ibody to meet its metabolic needs. Arrhythmia is the loss of cardiac rhythm, especially 
(irregularity of the heartbeat. CHD is often the result of a lack of oxygen and decreased 
~; 
~' 
' for absent blood flow to the myocardium, resulting from the narrowing or obstruction of 
~:coronary arteries. MI is the rapid development of myocardial necrosis caused by a 
' ; critical imbalance between oxygen supply and demand of the myocardium. Stroke is a 
rapid loss of brain function due to an interruption in the blood supply to all or parts of 
the brain. Venous thromboembolism is the formation of a clot or thrombus within the 
venous circulation, obstructing the flow of blood through the circulatory system. 
(ii) Signs and Symptoms 
The general and non-specific signs and symptoms of cardiovascular diseases are 
chest discomfort such as pressure, fullness or chest pain that lasts more than a few 
minutes or is intermittent, in addition to shortness of breath with or without chest pain, 
oedema, increased heart rate, fatigue, lack of appetite and nausea. 
(iii) Risk Factors 
Risk factors for cardiovascular diseases include age, family history of 
cardiovascular diseases, DM, hypertension, hyperlipidaemia, smoking, obesity and 
psychological factors such as depression and anxiety. Other risk factors specific to 
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1ESRD patients include anaem1a, hyperhomocysteinaemia, hyperparathyroidism, 
• oxidative stress, hypoalbuminaemia, chronic inflammation and prothrombotic factors 
(National Kidney Foundation, 2005). 
(iv) Epidemiology 
A study conducted in collaboration with the Ministry of Health, Malaysia and 
( the World Health Organization (WHO) revealed that CHD and stroke were among the 
t . 
~. five most common diseases in Malaysia. Another study conducted on 21,708 
1 
~ Malaysians aged 30 years and above revealed that at least 61% had cardiovascular 
' ~ diseases risk, while 27% had two or more risk factors (Lim et a/, 2000). 
k ~ 
t 
~ 
t 
(v) Management 
The initial management of cardiovascular diseases involves lifestyle 
modifications such as smoking cessation, regular exercise and healthy diet. Patients i ~.· with CKD and cardiovascular diseases require regular assessment and treatment of the 
r 
' traditional risk factors (e.g., DM, hypertension, hyperlipidaemia, anaemia and mineral [ 
~· metabolism abnormalities) as recommended by the NKF-KDOQI guidelines (National 
J Kidney Foundation, 2005). 
~· 
(vi) Complications 
It has been reported that cardiovascular diseases are the primary cause of death 
among ESRD patients (Wong et al., 2005; Go et al., 2004). 
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(b) Hypertension 
(i) Definition: 
Hypertension is defined as a persistent systolic BP of 140 mmHg or higher 
- .... ..,.,,-.r a persistent diastolic BP of 90 mmHg or higher. For patients with CKD, a 
l[q,ifstc>llC BP of < 130 mmHg and a diastolic BP of < 80 mmHg is recommended as a 
•urrgc~t to reduce the risk of cardiovascular disease (National Kidney Foundation, 2004). 
(ii) Causes 
Hypertenion results from either a specific cause (e.g. secondary hypertension) 
an underlying pathophysiologic mechanism (e.g. primary or essential hypertension) . 
. Sp~cific causes of secondary hypertension are polycystic kidney disease, renovascular 
hypertension, hydronephrosis, Cushing's syndrome, aldosteronism, 
pheochromocytoma, hypothyroidism, hyperthyroidism, sleep apnea and obesity (Ooi et 
a/., 1970; Chapman and Schrier 1991; Calhoun, 2006; Saito eta/., 1983; Nieto eta/., 
2000). Underlying pathophysiologic mechanisms that cause primary or essential 
hypertension include atherosclerosis, increased vascular reactivity due to excess 
sodium intake and increased intracellular calcium concentration (Campese eta!., 1996). 
(iii) Epidemiology 
The Third National Health and Nutrition Examination Survey (NHANES III) 
reported that hypertension was present in 24% of American population (Burt et a!., 
1995). In 2004, the prevalence of hypertension in Malaysian adults was estimated to be 
33% (Lim and Morad, 2004). The prevalence of hypertension is similarly high in 
Singapore (27.3%), Korea (22.9%) and India (25% urban and 10% rural subjects) 
(Ministry of Health, Singapore, 2001; Choi eta/., 2006; Gupta, 2004). 
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